Published in Nat Chem Biol on August 30, 2009
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol (2010) 6.91
Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell (2010) 3.82
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell (2011) 2.35
The (un)targeted cancer kinome. Nat Chem Biol (2010) 2.33
A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell (2013) 1.84
Turning enzymes ON with small molecules. Nat Chem Biol (2010) 1.47
Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc Natl Acad Sci U S A (2011) 1.33
Regulation of the catalytic activity of the EGF receptor. Curr Opin Struct Biol (2011) 1.26
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
The ins and outs of selective kinase inhibitor development. Nat Chem Biol (2015) 0.98
Dynamics-Driven Allostery in Protein Kinases. Trends Biochem Sci (2015) 0.96
Exploiting protein flexibility to predict the location of allosteric sites. BMC Bioinformatics (2012) 0.93
Comparing Conformational Ensembles Using the Kullback-Leibler Divergence Expansion. J Chem Theory Comput (2012) 0.93
Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem (2009) 0.92
Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J Biol Chem (2010) 0.91
Regulation of the interaction between protein kinase C-related protein kinase 2 (PRK2) and its upstream kinase, 3-phosphoinositide-dependent protein kinase 1 (PDK1). J Biol Chem (2009) 0.90
Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP. J Mol Biol (2010) 0.83
Allosteric regulation of glycogen synthase kinase 3β: a theoretical study. Biochemistry (2010) 0.83
A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. Proc Natl Acad Sci U S A (2014) 0.82
Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway. J Virol (2011) 0.80
PDK1 inhibitors. Pharm Pat Anal (2012) 0.79
PS48 can replace bovine serum albumin in pig embryo culture medium, and improve in vitro embryo development by phosphorylating AKT. Mol Reprod Dev (2015) 0.79
Guidelines for the successful generation of protein-ligand complex crystals. Acta Crystallogr D Struct Biol (2017) 0.79
Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by Its N-terminal domain. J Biol Chem (2012) 0.79
Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery. Pflugers Arch (2015) 0.78
Elastic network model of allosteric regulation in protein kinase PDK1. BMC Struct Biol (2010) 0.77
Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking. J Med Chem (2015) 0.77
Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase. J Biol Chem (2012) 0.76
Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods. Angew Chem Int Ed Engl (2015) 0.75
Chemical biology: Caught in the activation. Nature (2009) 0.75
Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. PLoS One (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
The protein kinase complement of the human genome. Science (2002) 35.36
Automated protein model building combined with iterative structure refinement. Nat Struct Biol (1999) 27.52
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell (2006) 20.92
Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr (2001) 15.88
The conformational plasticity of protein kinases. Cell (2002) 11.21
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science (1991) 9.99
Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J (2003) 4.65
Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell (2003) 4.51
Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev (2001) 4.38
Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol (2002) 3.77
A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J (2000) 3.70
The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J (2001) 3.58
Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell (2002) 3.53
Structural basis for control by phosphorylation. Chem Rev (2001) 3.53
Protein phosphorylation in signaling--50 years and counting. Trends Biochem Sci (2005) 3.19
Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J (2003) 2.89
In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J (2003) 2.74
A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J (2002) 2.72
Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J (2000) 2.67
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J (2002) 1.93
The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem (2005) 1.76
Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation. EMBO J (2007) 1.74
Crystal structure of an inactive Akt2 kinase domain. Structure (2003) 1.48
Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. Trends Biochem Sci (2004) 1.41
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J (2006) 1.37
In vivo role of the phosphate groove of PDK1 defined by knockin mutation. J Cell Sci (2005) 1.30
The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein. Structure (2004) 1.28
AGC protein kinase phosphorylation and protein kinase C. Biochem Soc Trans (2001) 1.23
Duplicated dockerin subdomains of Clostridium thermocellum endoglucanase CelD bind to a cohesin domain of the scaffolding protein CipA with distinct thermodynamic parameters and a negative cooperativity. Biochemistry (2002) 1.20
Regulation of protein kinases in insulin, growth factor and Wnt signalling. Curr Opin Struct Biol (2002) 1.20
Crystal structure of the kinase domain of serum and glucocorticoid-regulated kinase 1 in complex with AMP PNP. Protein Sci (2007) 1.11
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol Cell Proteomics (2005) 6.34
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70
The chemistry of two-dimensional layered transition metal dichalcogenide nanosheets. Nat Chem (2013) 4.57
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48
Single-layer MoS2 phototransistors. ACS Nano (2011) 3.43
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell (2009) 3.34
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology (2003) 3.09
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology (2002) 2.95
Fasting plasma glucose at 24-28 weeks to screen for gestational diabetes mellitus: new evidence from China. Diabetes Care (2013) 2.89
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Graphene-based composites. Chem Soc Rev (2011) 2.85
Growth of large-area and highly crystalline MoS2 thin layers on insulating substrates. Nano Lett (2012) 2.81
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J (2002) 2.72
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat Protoc (2006) 2.71
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med (2011) 2.49
Occult hepatitis C: how convincing are the current data? Hepatology (2009) 2.49
The evolution of dip-pen nanolithography. Angew Chem Int Ed Engl (2004) 2.49
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. Physiol Genomics (2007) 2.46
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol (2012) 2.45
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med (2008) 2.43
Calibrating the end-Permian mass extinction. Science (2011) 2.41
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol (2011) 2.40
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) 2.37
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) 2.35
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis (2005) 2.33
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci U S A (2010) 2.20
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genomics (2014) 2.15
Polymer pen lithography. Science (2008) 2.14
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol (2013) 2.08
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Chloride intracellular channel-4 is a determinant of native collateral formation in skeletal muscle and brain. Circ Res (2009) 2.02
Electrically conductive and optically active porous silicon nanowires. Nano Lett (2009) 2.00
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol (2009) 1.98
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology (2010) 1.96
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol (2004) 1.92
A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol (2011) 1.91
Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol (2007) 1.90
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature (2005) 1.86
Graphene-based materials: synthesis, characterization, properties, and applications. Small (2011) 1.85
G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain. J Neurosci (2005) 1.84
Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J (2007) 1.84
Depicting more accurate pictures of protistan community complexity using pyrosequencing of hypervariable SSU rRNA gene regions. Environ Microbiol (2010) 1.84
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82
Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol (2008) 1.82
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol (2006) 1.77